OncoSec Medical Inc (ONCSQ)

[hschlauch]

http://www.businesswire.com/news/home/20170830006308/en/New-Data-Epacadostat-Combination-KEYTRUDA®-pembrolizumab-Demonstrate

ORR: 30/54 (56%)

CR: 8/54 (15%)

PR: 2/54 (41%)

In advanced melanoma, all treatment naive.

Grade =3 TRAEs were observed in 17 percent of patients; the most common were increased lipase (n=4), rash (n=3), and increased amylase (n=2). Three patients discontinued for TRAEs. No treatment-related deaths occurred/quote]